A detailed history of Dagco, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Dagco, Inc. holds 480 shares of AMGN stock, worth $151,459. This represents 0.07% of its overall portfolio holdings.

Number of Shares
480
Previous 480 -0.0%
Holding current value
$151,459
Previous $136,000 9.56%
% of portfolio
0.07%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $102,170 - $123,332
380 Added 380.0%
480 $136,000
Q4 2023

Feb 15, 2024

BUY
$255.7 - $288.46 $25,570 - $28,845
100 New
100 $28,000
Q4 2021

Jan 24, 2022

SELL
$198.88 - $227.6 $204,846 - $234,428
-1,030 Closed
0 $0
Q3 2021

Nov 01, 2021

SELL
$212.27 - $248.7 $456,380 - $534,705
-2,150 Reduced 67.61%
1,030 $219,000
Q2 2021

Jul 12, 2021

SELL
$233.58 - $259.14 $114,454 - $126,978
-490 Reduced 13.35%
3,180 $775,000
Q1 2021

Apr 28, 2021

SELL
$221.91 - $258.6 $104,297 - $121,542
-470 Reduced 11.35%
3,670 $913,000
Q4 2020

Jan 28, 2021

SELL
$216.38 - $257.67 $10,819 - $12,883
-50 Reduced 1.19%
4,140 $952,000
Q2 2020

Jul 27, 2020

SELL
$197.81 - $242.74 $16,813 - $20,632
-85 Reduced 1.99%
4,190 $988,000
Q1 2020

Apr 30, 2020

SELL
$182.24 - $241.7 $43,737 - $58,008
-240 Reduced 5.32%
4,275 $867,000
Q4 2019

Feb 06, 2020

SELL
$189.21 - $243.2 $28,381 - $36,480
-150 Reduced 3.22%
4,515 $1.09 Million
Q3 2019

Oct 28, 2019

SELL
$174.11 - $208.62 $26,116 - $31,293
-150 Reduced 3.12%
4,665 $903,000
Q2 2019

Aug 08, 2019

SELL
$166.7 - $195.41 $12,502 - $14,655
-75 Reduced 1.53%
4,815 $887,000
Q1 2019

May 13, 2019

SELL
$180.87 - $203.88 $61,495 - $69,319
-340 Reduced 6.5%
4,890 $929,000
Q4 2018

Feb 14, 2019

BUY
$178.4 - $208.25 $933,032 - $1.09 Million
5,230 New
5,230 $1.02 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Dagco, Inc. Portfolio

Follow Dagco, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dagco, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Dagco, Inc. with notifications on news.